Magnesium Taurate for Health & Longevity

Created on 11/07/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Magnesium taurate is a supplement joining the mineral magnesium to taurine, an amino acid, of interest for heart health, blood pressure and blood sugar. It has barely been tested in people; studies of each part alone show small blood-pressure and blood-sugar benefits. Loose stools and, with reduced kidney function, dangerous magnesium buildup are the main risks. A plausible, low-cost magnesium source for people with low intake or rising blood pressure. (Full Review)

Protocol

Standard dose
125–250 mg elemental magnesium daily
About 1.4–2.8 g of the salt; products typically supply 125 mg per capsule
Single versus split dosing
Two meal-time doses
Splitting reduces diarrhea; follows common practice
Age considerations
125 mg start in adults over 70
eGFR confirmed before increases; common practice
Time to effect
Blood pressure
Within 1 month
From magnesium trials, not the salt
Mood
Within 2 weeks
From an unblinded magnesium chloride trial
Tissue repletion
Weeks to months
Serum magnesium is held steady by the kidneys

Benefits

Contraindications
  • Advanced chronic kidney disease (stage 4–5, eGFR below 30 mL/min/1.73 m², or dialysis)
  • Myasthenia gravis or high-grade heart block
  • Myeloid leukemia or myelodysplastic syndrome
Key Interactions
  • Fluoroquinolone and tetracycline antibiotics (ciprofloxacin, doxycycline)
  • Bisphosphonates (alendronate)
  • Statins (rosuvastatin)
  • Integrase inhibitors (dolutegravir)
  • Gabapentin
  • Proton pump inhibitors (omeprazole) and loop diuretics (furosemide)
  • Antihypertensive drugs (amlodipine)
  • Levothyroxine
  • Magnesium-containing antacids and laxatives (milk of magnesia)
Theoretical (inferred from mechanism)
  • Blood-pressure-lowering supplements (potassium, fish oil)
  • Energy drinks and standalone taurine
  • Sedatives and sleep drugs (zolpidem, benzodiazepines)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal upset and diarrhea, hypermagnesemia in reduced kidney function
  • Speculative: Taurine fueling myeloid leukemia, taurine intake above the observed safe level

Monitoring

Marker Target Why
Serum magnesium 1.8–2.3 mg/dL (0.75–0.95 mmol/L) Safety check; expected to rise
Red blood cell magnesium About 4.0–6.8 mg/dL, varying by laboratory Expected to rise
eGFR (with creatinine) 60 mL/min/1.73 m² or higher Safety check
Home blood pressure Below 120/80 mmHg Expected to fall; safety check on antihypertensives
Fasting glucose 70–99 mg/dL Expected to fall in people with high glucose

Cadence: Baseline panel before starting; serum magnesium and eGFR at 4 weeks after reaching the target dose, again at 3 months, then every 6–12 months; home blood pressure several times weekly for the first month, then weekly; fasting glucose at 3 months, then every 6–12 months.

Qualitative Assessment

  • Time to fall asleep and night waking
  • Stool consistency and frequency
  • Headache or migraine days per month
  • Mood, anxiety and irritability
  • Night cramps frequency
  • Lightheadedness on standing